ALK inhibitors in non-small cell lung cancer: the latest evidence and developments

por Sullivan, Ivana, Planchard, David
Publicado no Ther Adv Med Oncol (2016)

Editorial on the article entitled “brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial”

por Sullivan, Ivana, Planchard, David
Publicado no J Thorac Dis (2016)

Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line

por Sullivan, Ivana, Planchard, David
Publicado no Front Med (Lausanne) (2017)

The role of brigatinib in crizotinib-resistant non-small cell lung cancer

por Mezquita, Laura, Planchard, David
Publicado no Cancer Manag Res (2018)

Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience

por Sullivan, Ivana, Planchard, David
Publicado no Ther Adv Respir Dis (2016)

Oncogene addiction and immune escape: friends or foes?

por Abdayem, Pamela, Planchard, David
Publicado no Ann Transl Med (2020)

FLAURA strikes again: efficacy of osimertinib is independent of PD-L1 expression

por Abdayem, Pamela, Planchard, David
Publicado no Transl Lung Cancer Res (2020)

Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience

por Botticella, Angela, Mezquita, Laura, Le Pechoux, Cecile, Planchard, David
Publicado no Ther Adv Respir Dis (2019)

Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report

por Niu, Xiaomin, Sun, Yingjia, Planchard, David, Chiu, Luting, Bai, Jian, Ai, Xinghao, Lu, Shun
Publicado no Front Oncol (2021)

Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib

por Facchinetti, Francesco, Levy, Antonin, Ammari, Samy, Naltet, Charles, Lavaud, Pernelle, Aldea, Mihaela, Vasseur, Damien, Planchard, David, Besse, Benjamin
Publicado no Cancer Manag Res (2021)

Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer

por Schernberg, Antoine, Mezquita, Laura, Boros, Angela, Botticella, Angela, Caramella, Caroline, Besse, Benjamin, Escande, Alexandre, Planchard, David, Le Péchoux, Cécile, Deutsch, Eric
Publicado no PLoS One (2018)

Staging of nutrition disorders in non‐small‐cell lung cancer patients: utility of skeletal muscle mass assessment

por Antoun, Sami, Morel, Hugues, Souquet, Pierre‐Jean, Surmont, Veerle, Planchard, David, Bonnetain, Franck, Foucher, Pascal, Egenod, Thomas, Krakowski, Ivan, Gaudin, Hélène, Debieuvre, Didier
Publicado no J Cachexia Sarcopenia Muscle (2019)

ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer

por Passaro, Antonio, Addeo, Alfredo, Von Garnier, Christophe, Blackhall, Fiona, Planchard, David, Felip, Enriqueta, Dziadziuszko, Rafal, de Marinis, Filippo, Reck, Martin, Bouchaab, Hasna, Peters, Solange
Publicado no ESMO Open (2020)

Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non–Small Cell Lung Cancer

por Kas, Baptiste, Talbot, Hugues, Ferrara, Roberto, Richard, Colombe, Lamarque, Jean-Philippe, Pitre-Champagnat, Stéphanie, Planchard, David, Balleyguier, Corinne, Besse, Benjamin, Mezquita, Laura, Lassau, Nathalie, Caramella, Caroline
Publicado no JAMA Oncol (2020)

Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients

por Boros, Angela, Lacroix, Ludovic, Lacas, Benjamin, Adam, Julien, Pignon, Jean-Pierre, Caramella, Caroline, Planchard, David, de Montpreville, Vincent, Deutsch, Eric, Levy, Antonin, Besse, Benjamin, Pechoux, Cécile Le
Publicado no Oncotarget (2017)

Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

por Oulhen, Marianne, Pawlikowska, Patrycja, Tayoun, Tala, Garonzi, Marianna, Buson, Genny, Forcato, Claudio, Manaresi, Nicolò, Aberlenc, Agathe, Mezquita, Laura, Lecluse, Yann, Lavaud, Pernelle, Naltet, Charles, Planchard, David, Besse, Benjamin, Farace, Françoise
Publicado no NPJ Precis Oncol (2021)

A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer

por Yamamoto, Nobuyuki, Hayashi, Hidetoshi, Planchard, David, Morán, Teresa, Gregorc, Vanesa, Dowell, Jonathan, Sakai, Hiroshi, Yoh, Kiyotaka, Nishio, Makoto, Cortot, Alexis B., Benhadji, Karim A., Soni, Nital, Huang, Jinhong, Makris, Lukas, Cedres, Susana
Publicado no Invest New Drugs (2020)

Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer

por Park, Wungki, Mezquita, Laura, Okabe, Naoyuki, Chae, Young Kwang, Kwon, Deukwoo, Saravia, Diana, Auclin, Edouard, Planchard, David, Caramella, Caroline, Ferrara, Roberto, Agte, Sarita, Oh, Michael, Mudad, Raja, Jahanzeb, Mohammad, Suzuki, Hiroyuki, Besse, Benjamin, Lopes, Gilberto
Publicado no Br J Cancer (2019)

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay

por Remon, Jordi, Swalduz, Aurelie, Planchard, David, Ortiz-Cuaran, Sandra, Mezquita, Laura, Lacroix, Ludovic, Jovelet, Cecile, Rouleau, Etienne, Leonce, Camille, De Kievit, Frank, Morris, Clive, Jones, Greg, Mercier, Kelly, Howarth, Karen, Green, Emma, Pérol, Maurice, Saintigny, Pierre, Besse, Benjamin
Publicado no PLoS One (2020)

An open-label phase 2 trial of dabrafenib plus trametinib in patients with previously treated BRAF V600E–mutant metastatic non-small cell lung cancer

por Planchard, David, Besse, Benjamin, Groen, Harry J M, Souquet, Pierre-Jean, Quoix, Elisabeth, Baik, Christina S, Barlesi, Fabrice, Kim, Tae Min, Mazieres, Julien, Novello, Silvia, Rigas, James R, Upalawanna, Allison, D’Amelio, Anthony M, Zhang, Pingkuan, Mookerjee, Bijoyesh, Johnson, Bruce E
Publicado no Lancet Oncol (2016)